Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
暂无分享,去创建一个
M. Andreeff | H. Kantarjian | G. Garcia-Manero | J. Cortes | S. Verstovsek | F. Ravandi | S. Pierce | C. Bueso-Ramos | M. Keating | S. O'brien | J. Jorgensen | W. Wierda | S. Faderl | A. Ferrajoli | R. Garris | D. Thomas | C. Bueso‐Ramos | Rebecca E. Garris
[1] H. Kantarjian,et al. Anthracycline dose intensification in adult acute lymphoblastic leukemia , 2010, Cancer.
[2] H. Kantarjian,et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.
[3] H. Dombret,et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia , 2010, Haematologica.
[4] H. Kantarjian,et al. Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia. , 2009 .
[5] B. Storer,et al. Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD). , 2009 .
[6] C. Bloomfield,et al. Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). , 2009 .
[7] L. Medeiros,et al. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. , 2009, American journal of clinical pathology.
[8] H. Kantarjian,et al. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. , 2009, Hematology/oncology clinics of North America.
[9] H. Kantarjian,et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. , 2009, Blood.
[10] J. Castillo,et al. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. , 2009, Expert opinion on investigational drugs.
[11] J. Leonard,et al. Durable complete responses from therapy with combined epratuzumab and rituximab , 2008, Cancer.
[12] G. Basso,et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. , 2008, Blood.
[13] K. Do,et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. , 2008, Blood.
[14] M. Czuczman,et al. Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels , 2008, Clinical Cancer Research.
[15] H. Kantarjian,et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. , 2007, Blood.
[16] B. Bonavida,et al. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. , 2007, Cancer research.
[17] D. Thomas. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. , 2007, Hematology. American Society of Hematology. Education Program.
[18] F. Behm,et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. , 2006, Blood.
[19] H. Kantarjian,et al. Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.
[20] Michael L. Wang,et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Leonard,et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] G. Basso,et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection , 2005, Leukemia.
[24] H. Kantarjian,et al. Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.
[25] H. Kantarjian,et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. , 2004, Blood.
[26] Steven M Kornblau,et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.
[27] 謙 大間知. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.Coiffier B,et al.N Engl J Med 2002;346(4):235-42--CHOP+リツキシマブ併用療法は、CHOP療法を上回る治療法であり、DLBCLの治療動向に大きなimpactを与えた , 2004 .
[28] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[29] M. Andreeff,et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. , 2003, Blood.
[30] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[31] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[32] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[33] Malone Dg. Mechanism of action of rituximab. , 2001 .
[34] D. Maloney. Mechanism of action of rituximab. , 2001, Anti-cancer drugs.
[35] P. Brousset,et al. PCR Analysis of Immunoglobulin Heavy Chain (IgH) and TcR-γ Chain Gene Rearrangements in the Diagnosis of Lymphoproliferative Disorders: Results of a Study of 525 Cases , 2000, Modern Pathology.
[36] M. Andreeff,et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] E. Weir,et al. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection , 1999, Leukemia.
[38] L. Ginaldi,et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.
[39] G. Pizzolo,et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin , 1998, Leukemia.
[40] A. Look,et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. , 1997, Blood.
[41] E. Estey,et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] C. Pui,et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[44] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[45] D.,et al. Regression Models and Life-Tables , 2022 .